# EDGAR Filing Document

**Accession Number:** 0001597553
**File Stem:** 0001104659-25-073158
**Filing Date:** 2025-8
**Character Count:** 10923
**Document Hash:** 731fb1f7d49d0fdb115e0ce7f08e1ecf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-073158.hdr.sgml**: 20250801

**ACCESSION NUMBER**: 0001104659-25-073158

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250801

**DATE AS OF CHANGE**: 20250801

**EFFECTIVENESS DATE**: 20250801

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sage Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001597553
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-277049
- **FILM NUMBER:** 251177103

**BUSINESS ADDRESS:**
- **STREET 1:** 55 CAMBRIDGE PARKWAY
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-299-8380

**MAIL ADDRESS:**
- **STREET 1:** 55 CAMBRIDGE PARKWAY
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**As filed with the Securities and Exchange Commission on August 1, 2025** 

**Registration No. 333-280460**

**Registration No. 333-277049**

**Registration No. 333-273754**

**Registration No. 333-269818**

**Registration No. 333-266455**

**Registration No. 333-262948**

**Registration No. 333-253431**

**Registration No. 333-236680**

**Registration No.** **333-229732**

**Registration No. 333-228246**

**Registration No. 333-223146**

**Registration No. 333-216202**

**Registration No. 333-209831**

**Registration No. 333-204549**

**Registration No. 333-197498**

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-280460**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-277049**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-273754**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-269818**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-266455**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-262948**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-253431**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-236680**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-229732**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-228246**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-223146**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-216202**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-209831**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-204549**

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-197498**

***Under***

***The Securities Act of 1933***

**SAGE THERAPEUTICS, INC.** 

**(Exact name of Registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **27-4486580** |
| **(State or other jurisdiction of <br> incorporation or organization)** | **(I.R.S. Employer<br> Identification Number)** |
| **55 Cambridge Parkway <br> Cambridge, Massachusetts** | **02142** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Sage Therapeutics, Inc. 2011 Stock Option and Grant Plan, as amended**

**Sage Therapeutics, Inc. Amended and Restated 2016 Inducement Equity Plan, as amended**

**Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan, as amended**

**Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan**

**Sage Therapeutics, Inc. 2024 Equity Incentive Plan**

**(Full title of the plan)** 

**Jack A. Khattar**

**President and Treasurer** 

**Sage Therapeutics, Inc.**

**9715 Key West Avenue**

**Rockville, Maryland 20850**

**(Name and address of agent for service)** 

**Telephone: (301) 838-2500**

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

**Mark I. Gruhin, Esq.**

**George A. Naya, Esq.**

**Saul Ewing LLP**

**1919 Pennsylvania Avenue NW, Suite 550**

**Washington, DC 20006**

**Telephone: (202) 333-8800**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | x | Accelerated filer | ¨ |
| Non-accelerated filer | ¨ | Smaller reporting company | ¨ |
|  |  | Emerging growth company | ¨ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**DEREGISTRATION OF SECURITIES** 

This Post-Effective Amendment to the following Registration Statements on Form S-8 (each, a "**Registration Statement**" and collectively, the "**Registration Statements**"), previously filed with the U.S. Securities and Exchange Commission (the "**SEC**"), is being filed by Sage Therapeutics, Inc., a Delaware corporation ("**Sage**"), to remove and withdraw from registration all securities registered pursuant to the Registration Statements that remain unissued and unsold:

&nbsp;&nbsp;&nbsp;&nbsp;· Registration Statement on Form S-8 (File No. 333-280460), originally filed with the SEC on June 25, 2024, pertaining to the registration of 16,502,166 shares of Sage's common stock, $0.0001 par value (the "**Shares**") under 2024 Equity Incentive Plan.

· Registration Statement on Form S-8 (File No. 333-277049), originally filed with the SEC on February 14, 2024, pertaining to the registration of 2,401,745 Shares under Sage's 2014 Stock Option and Incentive Plan.

· Registration Statement on Form S-8 (File No. 333-273754), originally filed with the SEC on August 7, 2023, pertaining to the registration of 500,000 Shares under Sage's 2014 Employee Stock Purchase Plan.

· Registration Statement on Form S-8 (File No. 333-269818), originally filed with the SEC on February 16, 2023, pertaining to the registration of 2,380,365 Shares under Sage's 2014 Stock Option and Incentive Plan.

· Registration Statement on Form S-8 (File No. 333-266455), originally filed with the SEC on August 2, 2022, pertaining to the registration of 300,000 Shares under Sage's 2014 Employee Stock Purchase Plan.

· Registration Statement on Form S-8 (File No. 333-262948), originally filed with the SEC on February 24, 2022, pertaining to the registration of 2,357,482 Shares under Sage's 2014 Stock Option and Incentive Plan.

· Registration Statement on Form S-8 (File No. 333-253431), originally filed with the SEC on February 24, 2021, pertaining to the registration of 2,332,336 Shares under Sage's 2014 Stock Option and Incentive Plan.

&nbsp;&nbsp;&nbsp;&nbsp;· Registration Statement on Form S-8 (File No. 333-236680), originally filed with the SEC on February 27, 2020, pertaining to the registration of 2,075,087 Shares under Sage's 2014 Stock Option and Incentive Plan.

· Registration Statement on Form S-8 (File No. 333-229732), originally filed with the SEC on February 19, 2019, pertaining to the registration of 1,875,530 Shares under Sage's 2014 Stock Option and Incentive Plan.

· Registration Statement on Form S-8 (File No. 333-228246), originally filed with the SEC on November 07, 2018, pertaining to the registration of 1,200,000 Shares under Sage's Amended and Restated 2016 Inducement Equity Plan.

· Registration Statement on Form S-8 (File No. 333-223146), originally filed with the SEC on February 22, 2018, pertaining to the registration of 1,680,117 Shares under Sage's 2014 Stock Option and Incentive Plan.

· Registration
 Statement on Form S-8 (File No. 333-216202), originally filed with the SEC on February 23, 2017, pertaining to the registration of
 2,000,000 Shares under Sage's 2016 Inducement Equity Plan and 1,488,886 Shares under Sage's 2014 Stock Option and
 Incentive Plan.

· Registration Statement on Form S-8 (File No. 333-209831), originally filed with the SEC on February 29, 2016, pertaining to the registration of 1,154,653 Shares under Sage's 2014 Stock Option and Incentive Plan.

· Registration Statement on Form S-8 (File No. 333-204549), originally filed with the SEC on May 29, 2015, pertaining to the registration of 773,779 Shares under Sage's 2014 Stock Option and Incentive Plan.

· Registration Statement on Form S-8 (File No. 333-197498), originally filed with the SEC on July 18, 2014 pertaining to the registration of 1,880,453 Shares under Sage's 2011 Stock Option and Grant Plan, 1,768,508 Shares under Sage's 2014 Stock Option and Incentive Plan and 282,000 Shares under Sage's 2014 Employee Stock Purchase Plan.

On July 31, 2025, pursuant to that certain Agreement and Plan of Merger, dated as of June 13, 2025, by and among Sage, Supernus Pharmaceuticals, Inc., a Delaware corporation ("**Supernus**"), and Saphire, Inc., a Delaware corporation and wholly owned subsidiary of Supernus ("**Purchaser**"), Purchaser merged with and into Sage (the "**Merger**"), with Sage surviving the Merger as a wholly owned subsidiary of Supernus.

As a result of the Merger, Sage has terminated all offerings of Sage's securities. In accordance with undertakings made by Sage in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold or not yet issued at the termination of the offering, Sage hereby removes from registration all such securities of Sage registered pursuant to the Registration Statements that remain unsold or not yet issued as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, Sage certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland, on August 1, 2025.

---

| | |
|:---|:---|
| **SAGE THERAPEUTICS, INC.** | **SAGE THERAPEUTICS, INC.** |
| By: | /s/ Jack A. Khattar |
| Name: | Jack A. Khattar |
| Title: | President and Treasurer |

---

No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.